- Abstract Number: 1243
A Patient-Focused Program for Using Steroids Wisely
- Abstract Number: 2023
A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout
- Abstract Number: 2253
A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB002, an Anti-TNFα mAb Designed for Extended Half-life, in Healthy Volunteers
- Abstract Number: 2254
A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB004, a CTLA-4-Ig Fusion Protein Designed for Increased Binding Affinity and Extended Half-life, in Healthy Volunteers
- Abstract Number: 2008
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Dose of ABP-671 in Participants with Chronic Kidney Disease (CKD)
- Abstract Number: 1753
A Phase 1, Multicenter, Open-Label Study to Establish the Preliminary Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process, for Severe, Refractory Autoimmune Diseases
- Abstract Number: 1121
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AMG 329, a Monoclonal Antibody, in Conventional and Plasmacytoid Dendritic Cell-Mediated Rheumatic Diseases
- Abstract Number: 1760
A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Mitogen-activated Protein Kinase-Activated Protein Kinase 2 (MK2) Inhibitor in Active Ankylosing Spondylitis
- Abstract Number: L08
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Parallel-group Study to Evaluate the Safety and Efficacy of XG005 in Subjects with Painful Osteoarthritis of the Knee
- Abstract Number: 0775
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings
- Abstract Number: 2108
A Pilot Randomized Controlled Trial for Hand Osteoarthritis
- Abstract Number: 1036
A Pilot Trial of Integrating Patient-Reported Outcome Measurement Information System (PROMIS®) into Rheumatology Care
- Abstract Number: 0536
A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease
- Abstract Number: 1428
A Post-hoc Analysis of Two Phase 2 Randomized Controlled Trials in Patients with Active Sjogren’s Disease Exploring the Novel Composite Endpoint Sjögren’s Tool for Assessing Response (STAR)
- Abstract Number: 2462
A Potent Inhibitor of PAI-1, MDI-2517, Mitigates Disease Severity in Preclinical Models of Systemic Sclerosis
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 182
- Next Page »